Cognition Therapeutics (CGTX) Stock: Buy, Sell, or Hold?
CGTX - Cognition Therapeutics, Inc. Common Stock
$0.98
0.00 (0.32%)
▲
5d:
-6.4%
30d:
-5.5%
90d:
-18.1%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGTX is currently trading at $0.98, which is considered oversold relative to its 30-day fair value range of $0.99 to $1.06.
Technical Outlook: Technically, CGTX is in a strong uptrend. The price is currently testing key support at $0.97. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGTX scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+239.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGTX is in a strong uptrend. The price is currently testing key support at $0.97. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGTX scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.33 (+239.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.99 -
$1.06
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 239.2% below Wall St target ($3.33)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.97
Resistance Level
$1.07
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.47
Wall Street Target
$3.33
(+239.2%)
Share & Embed Analysis
Last updated: September 13, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGTX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John Brendan Doyle
BUY
10000 shares
2026-04-16
Lisa Ricciardi
BUY
9175 shares
2026-04-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
